Our Company was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. Our Company became a deemed public company under section 43A (1A) of the Companies Act, 1956 with effect from July 1, 1993 and the word `Private' was removed from the name of our Company and the certificate of incorporation of our Company was endorsed by the Registrar of Companies, Maharashtra at Bombay to that effect. Subsequently, our Company was converted from a deemed public company into a public company upon amendment of section 43A of the Companies Act, 1956 by the Companies Amendment Act, 2000 and the name of our Company was changed to `Emcure Pharmaceuticals Limited', pursuant to our Shareholders resolution dated August 20, 2001 and a certificate of change of name was issued by the RoC on September 18, 2001.
Major events and milestones: 1981 -Our Company was incorporated as Emcure Pharmaceuticals Private Limited
1999 -Amalgamation of Lasor Drugs Limited with our Company
2001 -Our Company was converted from a deemed public company into a public company -Amalgamation of Emcure Laboratories Private Limited, Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiralal Mehta Sales Private Limited with our Company. -Our Subsidiary, Gennova Biopharmaceuticals Limited was incorporated in India
2002 -Our Company received an approval to manufacture "S (-) Amlodipine Besilate tablets Asomex - 2.5" from the Joint Commissioner, Food and Drugs Administration, Pune, Maharashtra, India -Our Subsidiary, Zuventus Healthcare Limited, was incorporated in India
2006 -Blackstone GPV Capital Partners Mauritius V-C Ltd. subscribed to 226,325 Equity Shares of face value of ?10 each of our Company and 17,931,642 optionally convertible redeemable preference shares of our Company for the total investment of ?2,250 million. -Our Company established a facility at Kurkumbh, Pune, Maharashtra, India -Our Company commenced operations of injectables facility at Hinjawadi, Pune, Maharashtra, India
2007 -Facility established by our Subsidiary, Gennova at Hinjawadi, Pune, Maharashtra, India became operational -Our Subsidiary, Gennova received an approval from the Central Drugs Standard Control Organisation to start manufacturing "Recombinant Tissue Plasminogen Activator (TNK-t-PA)" -Our Subsidiary, Emcure Nigeria Limited, was incorporated in Nigeria
2009 -Our Company commenced production of tablets and capsules at our facility at Jammu, Jammu and Kashmir, India.
2010 -Our Subsidiary, Emcure Pharmaceuticals Mena FZ-LLC was incorporated in Dubai -Our Subsidiary, Emcure Pharmaceuticals South Africa (Pty) Ltd, was incorporated, in South Africa
2011 -Our Subsidiary, Emcure Brasil Farmaceutica LTDA, was incorporated, in Brazil
2012 -Our Company acquired rights of BICNU -Our Subsidiary, Emcure Pharma UK Ltd., was incorporated in the United Kingdom
2014 -BC Investments IV Limited acquired 13.09% of the then existing equity share capital of our Company (i.e., 5,918,386 Equity Shares of face value of ?10 each) from Blackstone GPV Capital Partners Mauritius V-C Ltd. -Our Subsidiary, Emcure UK acquired Tillomed Laboratories Limited -Our Subsidiary, Emcure Pharma Peru S.A.C., was incorporated in Peru -Our Subsidiary, Emcure Pharma Mexico S.A. DE C.V., was incorporated in Mexico -Our Subsidiary, Zuventus, obtained consent for establishment of industrial unit from Department of Commerce and Industries, Government of Sikkim, India
2015 -Our Company entered into Canada through acquisition of Marcan Pharmaceuticals Inc. -Our Subsidiary, Emcure Pharmaceuticals Pty Ltd., was incorporated in Australia
2016 -Tenecteplase (TNK - t - PA), manufactured by Gennova, approved for additional indication i.e., in thrombolytic treatment of the acute ischemic stroke within three hours of stroke initiation by the Directorate General of Health Services, CDSCO - Biological Division, Government of India -Our Subsidiary, Emcure UK acquired Bhardwaj Pharma GmbH (now known as Tillomed Pharma GmbH) -Our, Subsidiary Emcure UK acquired Laboratorios Tillomed Spain SLU
2017 -Our Subsidiary, Zuventus, established a manufacturing facility at Bengaluru, Karnataka, India -Our Subsidiary, Tillomed Italia S.R.L, was incorporated in Italy
2018 -Our Company received a license to work a factory in relation to the manufacturing facility situated at Sanand, Gujarat, India. -Our Subsidiary, Tillomed France S.A.S., was incorporated in France
2020 -Our Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile
2021 -Our Subsidiary, Lazor Pharmaceuticals Limited, was incorporated in Kenya -Our Subsidiary, Emcure Pharma Philippines Inc., was incorporated in Philippines
2022 -Our Subsidiary, Tillomed Malta Ltd, was incorporated in Malta
2023 -Our Subsidiary, Marcan Pharmaceuticals Inc., acquired Mantra Pharma Inc
2024 -Emcure Pharmaceuticals launched Arth. -Emcure Pharma launches Emcutix. -Emcure Pharma teams up with moms to Normalise Breastfeeding in Public.
2025 -Emcure launched Poviztra, second brand of Novo Nordisk's weightloss drug Wegovy. -Emcure Pharma Gets CDSCO Panel Nod for Phase III Trial of Semaglutide in Chronic Weight Management. -Novo Nordisk inks collaboration with Emcure, to sell its weightloss and diabetes drug Wegovy.
|